158 related articles for article (PubMed ID: 30844536)
1. Biased signaling agonist of dopamine D3 receptor induces receptor internalization independent of β-arrestin recruitment.
Xu W; Reith MEA; Liu-Chen LY; Kortagere S
Pharmacol Res; 2019 May; 143():48-57. PubMed ID: 30844536
[TBL] [Abstract][Full Text] [Related]
2. Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors.
Min C; Zheng M; Zhang X; Caron MG; Kim KM
Br J Pharmacol; 2013 Nov; 170(5):1112-29. PubMed ID: 23992580
[TBL] [Abstract][Full Text] [Related]
3. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
[TBL] [Abstract][Full Text] [Related]
4. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor.
Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM
Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791
[TBL] [Abstract][Full Text] [Related]
5. A novel molecular mechanism responsible for phosphorylation-independent desensitization of G protein-coupled receptors exemplified by the dopamine D
Zheng M; Zhang X; Sun N; Min X; Acharya S; Kim KM
Biochem Biophys Res Commun; 2020 Jul; 528(3):432-439. PubMed ID: 32505358
[TBL] [Abstract][Full Text] [Related]
6. G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex. A case of autoreceptor regulation.
Kim KM; Gainetdinov RR; Laporte SA; Caron MG; Barak LS
J Biol Chem; 2005 Apr; 280(13):12774-80. PubMed ID: 15687500
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization.
Fiorentini C; Busi C; Gorruso E; Gotti C; Spano P; Missale C
Mol Pharmacol; 2008 Jul; 74(1):59-69. PubMed ID: 18424554
[TBL] [Abstract][Full Text] [Related]
8. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
Conroy JL; Free RB; Sibley DR
ACS Chem Neurosci; 2015 Apr; 6(4):681-92. PubMed ID: 25660762
[TBL] [Abstract][Full Text] [Related]
9. Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.
Guitart X; Navarro G; Moreno E; Yano H; Cai NS; Sánchez-Soto M; Kumar-Barodia S; Naidu YT; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Ferré S
Mol Pharmacol; 2014 Oct; 86(4):417-29. PubMed ID: 25097189
[TBL] [Abstract][Full Text] [Related]
10. G-protein biased signaling agonists of Dopamine D3 receptor promote distinct activation patterns of ERK1/2.
Xu W; Bearoff F; Kortagere S
Pharmacol Res; 2022 May; 179():106223. PubMed ID: 35429668
[TBL] [Abstract][Full Text] [Related]
11. Clathrin-mediated endocytosis is responsible for the lysosomal degradation of dopamine D3 receptor.
Zhang X; Sun N; Zheng M; Kim KM
Biochem Biophys Res Commun; 2016 Aug; 476(4):245-251. PubMed ID: 27240955
[TBL] [Abstract][Full Text] [Related]
12. U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation.
Li JG; Luo LY; Krupnick JG; Benovic JL; Liu-Chen LY
J Biol Chem; 1999 Apr; 274(17):12087-94. PubMed ID: 10207034
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins.
Kim KM; Valenzano KJ; Robinson SR; Yao WD; Barak LS; Caron MG
J Biol Chem; 2001 Oct; 276(40):37409-14. PubMed ID: 11473130
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D
Kim KM
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047716
[TBL] [Abstract][Full Text] [Related]
15. RGS2 modulates the activity and internalization of dopamine D2 receptors in neuroblastoma N2A cells.
Luessen DJ; Hinshaw TP; Sun H; Howlett AC; Marrs G; McCool BA; Chen R
Neuropharmacology; 2016 Nov; 110(Pt A):297-307. PubMed ID: 27528587
[TBL] [Abstract][Full Text] [Related]
16. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
[TBL] [Abstract][Full Text] [Related]
17. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
[TBL] [Abstract][Full Text] [Related]
18. Prolonged dopamine D
Luis-Ravelo D; Fumagallo-Reading F; Castro-Hernandez J; Barroso-Chinea P; Afonso-Oramas D; Febles-Casquero A; Cruz-Muros I; Salas-Hernandez J; Mesa-Infante V; Rodriguez-Nuñez J; Gonzalez-Hernandez T
Pharmacol Res; 2021 Mar; 165():105434. PubMed ID: 33484816
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.
Free RB; Chun LS; Moritz AE; Miller BN; Doyle TB; Conroy JL; Padron A; Meade JA; Xiao J; Hu X; Dulcey AE; Han Y; Duan L; Titus S; Bryant-Genevier M; Barnaeva E; Ferrer M; Javitch JA; Beuming T; Shi L; Southall NT; Marugan JJ; Sibley DR
Mol Pharmacol; 2014 Jul; 86(1):96-105. PubMed ID: 24755247
[TBL] [Abstract][Full Text] [Related]
20. Targeting the dopamine D3 receptor: an overview of drug design strategies.
Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
